AMANDA MURPHY
Associate Director, Investor Relations & Public Relations, Aegerion Pharmaceuticals
Email: amanda.murphy@aegerion.com
Phone: 857-242-5024
Vancouver, British Columbia & Cambridge, MA, March 7, 2017 – Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the United States Patent Trial and Appeal Board (PTAB) issued a written decision in an Inter Partes Review proceeding affirming the patentability of all claims on U.S. 7,932,268 and U.S. 8,618,135 lomitapide dosage regimen patents.
Company Reports Preliminary Total Net Product Sales Expected to be Between $150 million and $152 million, Exceeding High End of Prior Guidance
Global Expansion Plans for Metreleptin Opportunity Underway
